盐酸伊立替康联合顺铂方案治疗宫颈癌的临床疗效及安全性分析

Analysis of clinical efficacy and safety of irinotecan combined with cisplatin in the treatment of cervical cancer

目的探讨盐酸伊立替康与顺铂联合方案对宫颈癌治疗的安全性及疗效分析。方法选择2011-07-01—2014—03—31昌乐县人民医院收治的76例宫颈癌患者为研究对象，随机分为对照组38例，实施紫杉醇疗法；观察组38例，采取盐酸伊立替康联合顺铂方案治疗。对2组患者疗效及安全性作进一步分析。结果观察组总有效率为73．68％，明显较对照组的50．00％高，差异有统计学意义，P〈0．05；经化疗后，观察组不良反应发生率为28．95％，显著较对照组的50．00％低，差异有统计学意义，P〈0．05。结论顺铂联合盐酸伊立替康对宫颈癌患者治疗的效果显著，安全性高，可有效控制病情发展，值得临床推广。

OBJECTIVE To investigate the safety and efficacy of irinotecan hydroehloride and eisplatin in the treat- ment of cervical cancer. METHODS 76 cases of cervical cancer patients in our hospital from 2011 July to 2014 March were as the research object, randomly divided into control group 38 Cases, the implementation of paclitaxel therapy, the observation group 38 cases, taking effects of irinoteean combined with cisplatin in the treatment of, for further analysis of the two groups of patients with curative effect and safety. RESULTS The total effective rate of observation group was 73.68%, significantly higher than the control group 50.00%, the difference was statistically significant （P^0. 05） ; after the chemotherapy, the observation group the incidence of adverse reactions was 28. 95%, significantly lower than 50.00% in the control group, the difference was statistically significant （P〈0.05）. CONCLUSION Cisplatin and irino- teean hydrochloride Kang on cervical cancer patients with significant curative effect, high safety, can effectively control the progression of the disease, is worth the clinical Promotion.